

## Transmission of CMV, HTLV-1 and HIV through breast milk: science, policy and unknowns

\*Andrew J. Prendergast<sup>1,2</sup>, Aameena E. Goga<sup>3,4</sup>, Catriona Waitt<sup>5,6</sup>, \*Antoine Gessain<sup>7</sup>,

\*Graham P. Taylor<sup>8</sup>, Nigel Rollins<sup>9</sup>, \*Elaine J. Abrams<sup>10</sup>, E. Hermione Lyall<sup>11</sup>, \*Philippe Van de Perre<sup>12</sup>

<sup>1</sup>Blizard Institute, Queen Mary University of London, UK

<sup>2</sup>Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe

<sup>3</sup>South African Medical Research Council, Cape Town, South Africa

<sup>4</sup>Department of Paediatrics, University of Pretoria, South Africa

<sup>5</sup>Department of Molecular and Clinical Pharmacology, University of Liverpool, UK

<sup>6</sup>Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda

<sup>7</sup>EPVO Unit, Institut Pasteur, Paris, France

<sup>8</sup>Section of Virology, Imperial College London, UK

<sup>9</sup>Department of Maternal, Newborn, Child & Adolescent Health, World Health Organization, Geneva, Switzerland

<sup>10</sup>ICAP at Columbia, Mailman School of Public Health, and Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA

<sup>11</sup>Department of Paediatrics, Imperial College Healthcare NHS Trust, London, UK

<sup>12</sup>Pathogenesis and Control of Chronic Infection, INSERM, University Montpellier, Etablissement Français du Sang, CHU de Montpellier, Montpellier, France

\*Full Professors are flagged with an asterix

Corresponding author: Professor Andrew J Prendergast, Blizard Institute, 4 Newark Street,  
London E1 2AT. Tel: +44 207 882 2269; Fax: +44 207 882 2195; Email:  
[a.prendergast@qmul.ac.uk](mailto:a.prendergast@qmul.ac.uk)

## **Summary**

Breastfeeding is a critical child survival intervention. The potential for transmission of some viral infections from mother-to-child, however, presents the dilemma of how best to interpret the benefits and risks of breastfeeding in different settings. Here, we compare the transmission dynamics, risk factors and outcomes of infection with three chronic viruses transmitted through breast milk: cytomegalovirus (CMV), human T-cell lymphotropic virus type 1 (HTLV-1), and human immunodeficiency virus (HIV). We provide an overview of current intervention approaches and discuss scientific, policy and programming gaps in our understanding of these major global infections.

### **Key messages:**

- Three viruses are known to be transmitted through breastfeeding and to result in chronic infection: CMV, HTLV-1 and HIV.
- CMV transmission through breast milk mostly leads to subclinical infection, except in preterm infants in whom severe clinical disease can occur; the best preventive and treatment approaches in this group remain unclear and more data are needed on long-term sequelae.
- HTLV-1 is restricted to specific geographic foci and can be transmitted from mother-to-child through breastfeeding in 10-25% of cases; the best preventive strategy is avoidance or shortening of breastfeeding where safe alternatives are available.
- The absolute transmission risk of HIV through breastfeeding in the context of suppressive maternal antiretroviral therapy is now low, even over extended periods.
- Guidance for infant feeding for women living with HIV varies by setting: in low- and middle-income countries, breastfeeding with suppressive ART and adherence support is recommended, while in high-income settings formula feeding is advised.

**Key words:** CMV; HTLV-1; HIV; breastfeeding; virus; infant; survival.

## **Introduction**

Optimal breastfeeding is a critical intervention in the quest to ensure that all children survive and thrive<sup>1, 2</sup>. Early breastfeeding within the first hour of birth and exclusive breastfeeding (meaning no other food or liquids except prescribed medications) for six months, reduce all-cause under-5-year child mortality<sup>1, 2</sup>. However, breastfeeding can also transmit infections. Three viruses are of particular global importance, since they can be transmitted from mother-to-child and lead to chronic infection: cytomegalovirus (CMV), Human T-cell Lymphotropic Virus type 1 (HTLV-1) and Human Immunodeficiency Virus (HIV). Particularly where prolonged breastfeeding for 12-24 months postpartum is usual, this provides a long duration of exposure to a potential source of infection and therefore presents a dilemma: how best to interpret the benefits and risks of breastfeeding in different settings. In this Review, we discuss the basic science, global public health approaches and policy gaps in our understanding of mother-to-child transmission (MTCT) of these three viruses.

## **Breastfeeding shapes infant development**

Breast milk is more than just food: it contains a suite of beneficial components including immunoglobulins, immune cells, stem cells, exosomes, growth factors, cytokines, lactoferrin and oligosaccharides<sup>3</sup>. Breast milk is extraordinarily adaptive, and its composition is governed by multiple factors including mode of delivery<sup>4</sup>, time from birth<sup>5</sup>, geography<sup>6</sup>, sex<sup>7</sup> and infant illness<sup>8</sup>. The mother-infant pair is intimately linked through breastfeeding. The concept of a common maternal-infant mucosal immune system<sup>9</sup> derives from observations that B-cells primed in the mother provide a source of infant immunoglobulins, and maternal immune cells penetrate the infant gut to populate the newborn, providing long-term protection through a process termed maternal micro-chimerism<sup>10, 11</sup>. Breast milk contains a rich microbial community<sup>12</sup>, helping to establish the infant intestinal microbiota, which is further shaped by breast milk glycans such as human milk oligosaccharides<sup>13</sup>. Bacterial

colonisation of the infant gut drives immune homeostasis and promotes intestinal maturation, including production of the mucus layer, antimicrobial peptides and gut barrier function<sup>14</sup>.

While the mature gut constitutes a remarkable defence system, the young infant gut remains vulnerable to infection during this dynamic period of intestinal adaptation. For example, the newborn has increased intestinal permeability for several weeks after birth to enable the process of maternal micro-chimerism<sup>11</sup>, which might facilitate passage of cell-associated viruses in breast milk; there is relative achlorhydria in the stomach, which impairs neutralisation of viruses<sup>15</sup>; and infants have a large population of intestinal CCR5+ memory CD4+ T-cells, which provide a highly susceptible pool of target cells for HIV<sup>16</sup>. Furthermore, exposure to viruses in early life occurs at a time when anti-viral immunity is not well developed due to enhanced tolerogenic responses, reduced Th1 development, and naïve lymphocyte predominance; the capacity to control viral infections only matures over the first few years<sup>17</sup>. However, any potential vulnerability associated with breastfeeding in the context of maternal viral infections must be interpreted against the proven protection of breastfeeding (Figure 1).

### **Mother-to-child transmission of viruses through breastfeeding**

Three viruses are known to be transmitted through breastfeeding and to result in chronic infection, with substantial clinical disease among some infants: CMV, HTLV-1 and HIV. By contrast, despite being found in milk, breastfeeding does not increase the risk of mother-to-child transmission for two other chronic viral infections of global importance, hepatitis B and C<sup>18, 19</sup>. The transmission dynamics and outcomes following MTCT are distinct for CMV, HTLV-1 and HIV (Table 1), and are influenced by maternal, infant, viral and environmental factors.

## CMV

CMV is a member of the ubiquitous Human Herpes Virus family; humans have been co-existing with these DNA viruses for millennia<sup>20</sup>. Primary CMV infection in the immunocompetent host is usually subclinical and the virus then establishes lifelong latency, with asymptomatic intermittent viral reactivation and excretion via body fluids<sup>21</sup>. Age at CMV acquisition varies geographically: in high-income countries, approximately 5-30% of children are CMV-seropositive by 5-6 years of age, compared with 85-95% in low- and middle-income countries (LMIC)<sup>21</sup>. In some LMIC, infection occurs almost universally during infancy: in a Gambian study, for example, 85% had acquired CMV by the age of 12 months<sup>22</sup>. Worldwide, CMV seropositivity among women of reproductive age therefore ranges from 40-100%, with higher seroprevalence in LMIC<sup>23</sup>.

More than 80% of seropositive women excrete CMV in breast milk<sup>24</sup>. Little or no virus is detectable in colostrum, but CMV DNA is increasingly detected in breast milk to a maximum level at 4-8 weeks of lactation, with subsequent decline, often to minimal levels<sup>25</sup>. CMV-seropositive women also excrete virus in the birth canal, saliva and urine; thus the exact route of early CMV transmission can be difficult to ascertain. CMV is excreted by mammary epithelium and is found in both the milk whey and cellular (leukocyte) compartments; cell-free virus in the whey is associated with a higher vertical transmission risk<sup>26</sup>. Mothers with earlier excretion of infectious virus, higher CMV milk viral loads and longer duration of excretion, are more likely to transmit CMV<sup>26-28</sup>. An intriguing recent study from Uganda suggested that infant-to-mother transmission of CMV can also occur, such that infants first acquire primary CMV, either from another child in the house or from their mother through breastfeeding, and then transmit the infection to their mother<sup>29</sup>.

Premature infants (<32 weeks' gestation) are at risk of symptomatic postnatal CMV infection<sup>24</sup>. The frequency of transmission and risk of clinical disease in preterm infants is not well established, since most studies have small numbers, lack good control groups, and report variable breast milk exposure durations. However, a meta-analysis of 695 premature infants breastfed by CMV-seropositive mothers (17 studies, median 38 infants per study, range: 7–90), found that CMV transmission ranged from 2-37%; CMV-related symptoms developed in 0-18%, and severe “sepsis-like” symptoms in 0-14% of infants<sup>30</sup>. Among the few studies reporting longer-term follow-up of premature infants ( $\leq 1500$ g birth weight) with postnatal CMV acquisition, some found no significant differences in outcomes compared to controls, while others suggested mild neurocognitive impairments<sup>31-33</sup>. Unlike congenital CMV infection, no sensorineural hearing loss has been found<sup>31, 33</sup>.

CMV breast milk transmission is obviated by pasteurisation, but this negatively affects other important breast milk components and is not feasible in many settings<sup>34</sup>. Freezing, ultraviolet-C irradiation and high-power microwave reduce CMV viral load and thus transmission, with less effect on other breast milk components, but more work is required to ascertain the best treatment methodologies, especially in the context of milk banks for preterm infants<sup>35-37</sup>. One study suggested freezing may increase the risk of necrotising enterocolitis, which has to be balanced with the risk of symptomatic CMV<sup>38</sup>. Some national guidelines suggest pasteurisation of breast milk for extreme preterm infants born to CMV-seropositive mothers until around 31 weeks' gestation, aiming to reduce the risk of transmission during the most vulnerable period<sup>39</sup>.

Women living with HIV have a higher risk of transmitting CMV than women without HIV, due to longer duration of CMV excretion and higher breast milk, cervical, and salivary CMV viral loads<sup>40, 41</sup>. In the only randomised controlled trial of breastfeeding versus formula feeding,



conducted among mothers living with HIV in Nairobi during the pre-antiretroviral therapy (ART) era, a secondary analysis of CMV transmission was undertaken in 138 breastfed and 134 formula-fed infants<sup>42</sup>. Overall, breastfed infants acquired CMV earlier than formula-fed infants (median age, 4.26 vs 9.87 months;  $P < 0.001$ ) and had a higher 1-year probability of CMV infection (0.89 vs 0.69;  $P < 0.001$ ), although the proportion with symptomatic infection was not reported. The risk of infant CMV acquisition was 1.6-fold greater (95% confidence interval 1.20, 2.16;  $P = 0.002$ ) with breastfeeding, independent of infant HIV status. HIV-infected infants who acquire postnatal CMV can develop severe symptomatic disease, and CMV is a co-factor for HIV disease progression in some studies<sup>43</sup>. There is some evidence that postnatal CMV may affect the immune development, growth and health of HIV-exposed uninfected infants, but more data are needed<sup>44</sup>. The impact of maternal ART on breast milk CMV viral load and postnatal transmission risk is heterogeneous<sup>45-47</sup> and it has been argued that new approaches to reducing postnatal CMV transmission among HIV-exposed infants are needed<sup>44</sup>.

Taken together, CMV transmission from mothers to infants occurs at high frequency and very early in life, particularly in LMIC and among women living with HIV. Postnatal infection in very preterm infants can cause clinical disease and strategies to prevent transmission through breast milk are needed. Whether CMV transmission through breastfeeding needs to be reduced in populations other than very preterm infants remains unclear. The available evidence suggests that CMV infection in HIV-unexposed term infants has limited clinical significance. More studies are needed to determine the impact of CMV on HIV-exposed infants.

## *HTLV-1*

HTLV-1, the first human retrovirus to be discovered in the early 1980s<sup>48</sup>, infects at least 5-10 million people worldwide, mainly in highly focal endemic areas such as southern Japan, West/Central Africa, the Caribbean and parts of South America and Australo-Melanesia<sup>49</sup>. Typically, adult prevalence in these endemic foci is around 1-2%, although up to 20-40% of people aged over 50 years are living with HTLV-1 in some areas<sup>49</sup>. HTLV-1 preferentially infects CD4+ T-cells, but CD8+ T-cells may also be important reservoirs; to a lesser extent, monocytes, B-cells, dendritic cells, and endothelial cells can be infected. Infection occurs by transmission of HTLV-1-infected cells between individuals, through semen, blood, and breast milk<sup>49</sup>. HTLV-1 infection is associated with two distinct diseases: a lymphoproliferative disorder termed Adult T-cell Leukaemia/Lymphoma (ATL), and an inflammatory neurological disease called tropical spastic paraparesis or HTLV-1-associated myelopathy (TSP/HAM). Acquisition of HTLV-1 during childhood is a major risk factor for the development of ATL<sup>50</sup>, which has a median age at diagnosis of around 50 years and usually runs a very aggressive course: the median survival in a case series from Jamaica was only 20 weeks<sup>51</sup>. Despite improvement in treatment approaches, the acute and lymphoma types of ATL still have a poor prognosis, with a 4-year survival of 11-16% in Japan between 2000-2009<sup>52</sup>. TSP/HAM typically has an insidious onset in adulthood, with sensory and bladder disturbance, together with slowly progressive pyramidal signs; however, a case series of children with early-onset disease in Bahia, Brazil was recently reported<sup>53</sup>. HTLV-1 is also associated with other inflammatory diseases such as infective dermatitis (mainly in children), uveitis and myositis.

MTCT of HTLV-1 occurs in 10-25% of breastfed infants<sup>49</sup>. Based on epidemiological, virological and experimental data, risk factors for MTCT have now been established. First, transmission of HTLV-1 increases with longer duration of breastfeeding: for example, in a prospective birth cohort in Jamaica, followed to at least 2 years of age, 19/60 (32%) children

who breastfed for longer than 12 months acquired HTLV-1, compared to 8/86 (9%) children who breastfed for less than 12 months<sup>54</sup>. Second, higher HTLV-1 proviral load in maternal blood and breast milk increases MTCT<sup>55, 56</sup>. The proviral load is a proxy for the number of infected cells, and reflects the fact that HTLV-1 transmission is cell-associated, and not due to cell-free virus. A recent longitudinal study showed that the proviral load is stable during pregnancy but elevated after delivery<sup>57</sup>. Finally, higher HTLV-1 antibody titres in maternal blood are associated with increased MTCT risk, which may partly reflect the correlation between antibody titres and maternal proviral load<sup>56</sup>. The processes underlying MTCT of HTLV-1 remain largely unknown, although potential mechanisms have recently been reviewed in detail<sup>58</sup>.

As there is no vaccine, and no antiretroviral regimen has been evaluated for PMTCT (or adult-to-adult transmission), the only preventive strategy is for mothers living with HTLV-1 to avoid breastfeeding. This approach has led to huge reductions in HTLV-1 MTCT in Japan. For example, in the Nagasaki Prefecture, the introduction of exclusive formula feeding was associated with a reduction of MTCT from 20.3% to 2.5%<sup>59</sup>. However, universal antenatal screening is currently only undertaken in Japan. In a recent open letter to the WHO<sup>60</sup>, experts have argued strongly for more action to prevent HTLV-1, including routine antenatal testing and avoidance or shortening of breastfeeding among mothers living with HTLV-1 where safe, alternative methods of infant feeding are available. Further research is needed to inform alternative approaches, including the role of maternal and/or infant antiretroviral prophylaxis in reducing HTLV-1 MTCT.

## *HIV*

In 2017, 36.9 million people globally were living with HIV, of whom 1.8 million were children<sup>61</sup>. Despite the enormous impact of PMTCT interventions, which have averted an

estimated 1.4 million new paediatric infections since 2010, around 180,000 children acquired HIV in 2017<sup>61</sup>. In the absence of any preventive interventions, transmission of HIV by breastfeeding is estimated to be 0.74% per month of breastfeeding<sup>62</sup> and contributes around one-third of the overall MTCT risk<sup>63</sup>; the relative contribution of postnatal transmission has increased in most breastfeeding countries following the increased coverage of antenatal PMTCT interventions<sup>64</sup>.

Cell-free and cell-associated viral loads in milk are major determinants of transmission<sup>65</sup>; other risk factors include the duration of breastfeeding<sup>62</sup>, severity of maternal immunodeficiency<sup>62</sup>, maternal immune response to HIV<sup>66</sup>, presence of an inflammatory process in the mammary gland (engorgement, mastitis, breast abscess)<sup>67</sup>, and early introduction of non-breast milk feeds (mixed feeding)<sup>68</sup>. With effective maternal HIV suppression on ART, the absolute transmission risk, even over extended periods, is less than 1% in trial settings<sup>69,70</sup>. However, the risk of postnatal transmission is extremely high (approximately 30%) if the mother acquires HIV while breastfeeding<sup>71</sup>, particularly among young infants, in whom the combination of high maternal HIV viral load and immature intestinal integrity may increase susceptibility to transmission<sup>71</sup>.

HIV actively replicates and produces viral particles during the whole duration of infection in adults, particularly in sub-mucosal compartments, which are rich in lymphoid cells<sup>72</sup>. HIV transmission can therefore arise from both cell-free and cell-associated reservoirs in breast milk<sup>73</sup>. Compared with lymphoid cells from blood, breast milk cells are more frequently activated memory cells, which express homing markers indicating their mucosal origin<sup>74</sup>. Quiescent CD4+ T-cells infected with HIV are also present in breast milk; if activated *ex vivo*, these cells are much more capable of producing infectious particles than corresponding blood cells<sup>74</sup>. *In vivo*, the activators of these quiescently infected cells may be co-infections,

since CMV and Epstein Barr virus DNA in milk are associated with shedding of HIV virions<sup>75</sup>. In addition, activated CD4+ T-cells with actively replicating HIV can be identified in breast milk of mothers on ART despite an undetectable plasma HIV viral load<sup>74</sup>. This activated reservoir may be particularly prone to cell-to-cell transfer of HIV in the infant, providing a residual source of postnatal transmission risk despite suppressive maternal ART<sup>64</sup>. Other cell types, such as macrophages and dendritic cells, may also be involved in the establishment of HIV reservoirs in the mammary gland and breast milk. Maternal micro-chimerism through breastfeeding, which seeds long-lived maternal cells into infant tissues, may include cells infected with HIV such as CD4+ progenitor T-cells, and may therefore represent an additional source of HIV transmission<sup>10, 11</sup>.

### **Preventing breast milk HIV transmission in LMIC settings**

Prior to availability of ART in LMIC settings, WHO recommended counselling of individual mothers living with HIV to choose between replacement feeding or breastfeeding, considering their living conditions and what method of feeding would most likely result in their infants surviving while remaining HIV-uninfected<sup>76, 77</sup>. Recommendations changed in 2010 following studies showing that ART significantly reduced HIV transmission risk, together with reports of increased mortality, morbidity and growth failure due to gastroenteritis and malnutrition among infants given replacement feeds as an HIV prevention strategy<sup>78, 79</sup>. There was increasing recognition that improving HIV-free survival, rather than preventing vertical HIV transmission alone, was the ultimate goal of PMTCT programmes. Consequently, the 2010 WHO recommendations introduced infant post-exposure prophylaxis throughout breastfeeding (PMTCT Option A) or maternal triple ART (PMTCT Option B) for HIV-exposed breastfeeding infants whose mothers were not receiving ART for their own health<sup>80</sup>. Within two years, these recommendations were rapidly adopted into policy in the vast majority of high HIV prevalence LMIC. Ministries of Health and local

communities had been grappling with the dilemma of preventing postnatal transmission without undermining breastfeeding as a child survival strategy; a public health approach of providing ART to all pregnant and lactating mothers living with HIV and recommending breastfeeding addressed these competing demands. Yet, even in these settings, it was noted that the 2010 WHO recommendations were not always “...translated into action by... front-line workers because of a variety of structural and ideological barriers”<sup>81</sup>.

In 2012, WHO guidelines recommended lifelong ART (referred to as Option B+) for all pregnant and breastfeeding women to simplify interventions and to amplify the gains beyond PMTCT, including preventing horizontal HIV transmission and protecting future pregnancies<sup>82</sup>. ART is now recommended for adults and children from the time of diagnosis<sup>83</sup>. As a result of these changes, multiparous mothers are now more likely to conceive on ART, nulliparous pregnant women more likely to initiate ART earlier in pregnancy, and breastfeeding mothers are more likely to be on ART. This earlier and increased antiretroviral use provides a platform for maternal viral load suppression and for eliminating mother-to-child HIV transmission (EMTCT), defined as <5% MTCT and ≤50 new paediatric HIV infections per 100,000 live births<sup>84</sup>. Although these updated policies have set the scene for EMTCT, data from LMIC indicate poor retention in care and ART adherence (73-76% antenatal adherence, falling to 55-65% postnatally)<sup>85-87</sup>. Although viral load monitoring during pregnancy, delivery and breastfeeding is gaining momentum, it is not yet fully integrated into routine care. Furthermore, although there is a correlation between plasma and breast milk viral loads, an undetectable plasma HIV viral load does not indicate lack of HIV infectivity, due to activated latent CD4+ T-cells in breast milk, even in the presence of antiretroviral drugs. Whilst ART for mothers living with HIV or extended prophylaxis for their infants in a clinical trial setting can reduce MTCT to <1% at 1-2 years of age<sup>69, 70</sup>, these results are not easily reproducible in real-life LMIC settings. The challenges

posed by inadequate maternal adherence, irregular virological monitoring, uncertain implications of low-level viraemia for MTCT, and residual breast milk infectivity, question the feasibility of eliminating breastfeeding MTCT in LMIC using present antiretroviral regimens. Thus, the evaluation of combination strategies, including maternal ART with support for adherence and maternal and/or infant passive immunoprophylaxis or active vaccination is a research priority.

### **Breastfeeding and HIV in high-income settings**

Avoidance of breastfeeding was the first effective PMTCT intervention for HIV in high-income countries. Based on a single case of transmission following transfusion-acquired postpartum HIV infection<sup>88</sup> and detection of HIV-1 in breast milk<sup>89</sup>, the first United States Centers for Disease Control and Prevention recommendation to undertake exclusive formula feeding was published in 1985<sup>90</sup>, and has been a core component of PMTCT guidelines in high-income countries ever since. Consequently, postpartum HIV MTCT in high-income countries is rare, and placing an infant at risk of HIV infection through breastfeeding has been considered a child protection issue in some settings<sup>91</sup>.

In 2009-2010, findings from several observational studies<sup>92-94</sup> and two randomised trials<sup>95,96</sup> highlighted the low rates of HIV transmission associated with breastfeeding in the context of either maternal combination ART or infant prophylaxis with nevirapine or other antiretroviral drugs. Guidelines in high-income countries have continued to recommend exclusive formula feeding regardless of maternal HIV viral load or therapy, since even with a consistently undetectable maternal viral load, the MTCT risk is low but not negligible. However, there has been a subtle but important shift in advice in high-income settings since these trial findings; for example, British HIV Association (BHIVA) guidelines in 2010 stated that “...if a woman is on effective HAART and has compelling reasons to breastfeed, she

should be supported to do so as safely, and for as short a period as possible". Current BHIVA guidelines<sup>97</sup> continue to recommend formula feeding, but provide advice regarding clinical and laboratory monitoring for women who decide to breastfeed after evidence-based counselling, similar to European<sup>98</sup> and US<sup>99</sup> guidelines.

In the context of sexual transmission, an undetectable viral load is now considered to indicate that HIV is untransmittable (so-called "U=U"). However, a similar confidence has not permeated the PMTCT context, for several possible reasons. There is a lack of data on transmission risk to provide accurate information to mothers; concerns regarding maternal adherence to ART; the potential for local HIV replication in the breast during episodes of mastitis; uncertainty regarding the impact of low-dose exposure to ART through breast milk; and intense monitoring is required during breastfeeding. High-quality evidence is therefore still needed to inform these issues and to guide recommendations on infant feeding by mothers living with HIV.

### **Exposure to antiretroviral drugs through breastfeeding**

Since current guidelines recommend that mothers living with HIV in LMIC undertake prolonged breastfeeding on ART<sup>83</sup>, it is essential to quantify the clinical importance of any adverse effects of infant ART exposure through breast milk. Factors influencing drug exposure in breastfed infants are shown in Figure 2. The peak concentrations of ART in breast milk lag behind those for plasma, and the elimination phase may be prolonged; such kinetics are seen for the nucleoside reverse transcriptase inhibitors (NRTIs)<sup>100</sup>. Exclusively breastfed infants receive up to 10% of the weight-adjusted infant dose of NRTIs and non-NRTIs (NNRTIs) whereas protease inhibitors have little transfer to the infant<sup>101</sup>. Genetic differences, such as CYP2B6 polymorphisms in the case of efavirenz, result in higher infant drug exposure<sup>102</sup>.



The major potential risk to the infant from exposure to maternal ART through breastfeeding is toxicity. However, it can be difficult to distinguish the effects of *in utero* and breast milk exposure to a drug. There has been considerable debate about the effects of infant exposure to tenofovir, although a recent systematic review suggests changes in bone mineral density have no clinical relevance<sup>103</sup>. Dolutegravir is the first integrase strand-transfer inhibitor to be studied in breastfeeding mother-infant pairs, and is measurable in both breast milk and the plasma of the breastfed infant<sup>104</sup>, but the clinical consequences are currently uncertain. Pharmacovigilance among infants exposed to drugs through breastfeeding is not well established, with under-reporting of adverse drug reactions, and a likely skew towards the most serious events<sup>105</sup>. Whilst few studies have systematically collected infant safety data, the recent PROMISE trial showed no increase in toxicities among infants exposed to ART through breast milk, compared to extended infant nevirapine prophylaxis<sup>69</sup>. Whilst the Antiretroviral Pregnancy Registry is well established, no parallel system exists to systematically collect data on clinical outcomes, growth and development in breastfed infants. Furthermore, the clinical tools needed to identify subtle toxicities have not been established.

Breast milk ART exposure may increase the risk of drug resistance among infants who acquire HIV. Secondary analysis of two large PMTCT trials indicated that, although MTCT rates were very low, infants who acquired HIV during breastfeeding while their mother was receiving ART had high rates (75-100%) of multi-class drug resistance, defined as resistance to both NRTIs and NNRTIs<sup>106, 107</sup>. Analysis of mother-infant pairs indicated that resistance arose in the infant as a result of selective drug pressure<sup>108</sup>. This risk likely remains in breastfeeding mothers who have poor adherence to therapy and is a potential challenge for future first-line treatment options among infants and young children.

An emerging clinical challenge is the impact of infant exposure to maternal ART, including during breastfeeding, on the accuracy of current early infant diagnosis protocols. Analysis of more than 13,000 HIV-exposed South African infants indicates an increase in equivocal results since 2015 among infants who are later confirmed as HIV-infected, in parallel with the change in guidelines to lifelong maternal ART and increased duration of breastfeeding. Maternal ART may reduce levels of infant viraemia and hence impair detection of HIV by PCR<sup>109</sup>. This warrants further evaluation programmatically.

### **Breast milk transmission of HIV: unknowns and future directions**

The ultimate goal of policies and programmes to prevent postnatal HIV transmission is for mothers to breastfeed their infants without consideration of their HIV status; three areas of research therefore remain essential. First, there is a need to improve the efficacy, flexibility and safety of ART regimens. Currently available interventions have transformed the landscape for infant and young child feeding in the context of HIV but they could be improved. Determining the most effective maternal and/or infant ART regimens during breastfeeding, while decreasing their adverse effects, will help increase coverage and bring transmission rates closer to zero. Second, learning how to identify all mothers living with HIV (especially those infected postpartum) and evaluating pre-exposure prophylaxis strategies to reduce incident infection during breastfeeding remains pivotal. Third, facility- and community-based interventions are needed to increase rates of retention-in-care of mothers, regardless of feeding practice. In Malawi, effective peer support increased postnatal retention in care and associated ART adherence to over 80% at 24 months with improved viral suppression and reduced resistance<sup>110</sup>.

As women living with HIV in high-income settings question their eligibility to breastfeed, and women in LMIC are currently advised to breastfeed without effective counselling on risks, the ethics of policies that argue for or against breastfeeding and the rights of women to choose an infant feeding practice need examination. Breastfeeding in the context of HIV has been a highly contested and divisive issue, often splitting the HIV and maternal-child health (MCH) communities. The integration of HIV-specific interventions into facility- and community-based MCH services is now a realistic policy and programme option; it is also an imperative as funding streams call for greater efficiencies.

## **Conclusions**

Breastfeeding remains critical to child survival globally. Recent insights into the science of breastfeeding, including the complex and adaptive properties of breast milk and the long-term benefits from its diverse range of constituents, demonstrate the importance of continuing to apply modern tools to an ancient and highly evolved practice. However, the risk of transmission through breastfeeding of three chronic viral infections of global health importance (CMV, HTLV-1 and HIV) has implications for public health policy. CMV transmission through breast milk is mostly of concern for preterm infants (<32 weeks or  $\leq 1500$ g birth weight) in whom severe clinical disease can occur. However, the best prevention and treatment approaches are currently uncertain, meaning practice varies across settings, and further data are needed on long-term sequelae. MTCT of HTLV-1, which is restricted to specific geographic foci, can be prevented by avoiding or shortening breastfeeding, provided safe alternatives are available. Guidelines for infant feeding by mothers living with HIV vary by setting: in LMICs, breastfeeding with maternal ART and adherence support is the recommended approach, while in high-income countries, exclusive formula feeding is advised, although some women on suppressive ART are now choosing to breastfeed.

There are some remaining gaps in our understanding of the transmission dynamics and potential interventions to reduce MTCT for these viruses (Panel). However, HIV is an excellent example of how our knowledge of viral kinetics and interventions has advanced since the virus was first identified in breast milk in 1985<sup>89</sup>, and how this understanding has impacted public health interventions for children. Research remains an essential mechanism for informing global guidelines and national policies and identifying viable options for intervention to maximize the benefits of breastfeeding while minimising the risks of viral transmission, to promote child health, development and long-term human capital.

### **Search strategy and selection criteria**

References for this Review were initially identified by each author based on their knowledge of the field. In addition, we searched PubMed using the search terms “CMV”, “HTLV-1”, “HIV”, “infant” and “breastfeeding” to identify additional studies, published in English, from inception up to 6<sup>th</sup> November 2018. The final reference list was generated based on inclusion of historical landmark studies, originality and relevance to the broad scope of this Review.

### **Declaration of interests**

EJA has participated in Viiv pharmaceuticals and Merck pharmaceuticals paediatric advisory committees. The other authors declared no conflicts of interest. The views expressed in this review are those of the individual authors and do not necessarily reflect the positions or recommendations of their institutions or organisations.

### **Funding**

AJP is funded by the Wellcome Trust (108065/Z/15/Z). AEG is supported by the South African Medical Research Council. CW is funded by a Wellcome Postdoctoral Training Fellowship for Clinicians (WT104422MA). GPT is supported by the NIHR Imperial Biomedical Research Centre.

### **Author contributions**

AJP and EHL drafted the section on CMV; AG and PVP drafted the section on HTLV-1; AJP, AEG, GPT and NR drafted the section on HIV; and CW and EJA drafted the section on antiretroviral exposure through breastfeeding. AJP integrated all author contributions and

produced the first draft of the manuscript, which was then reviewed and critically revised by all authors.

## References

1. Sankar MJ, Sinha B, Chowdhury R, et al. Optimal breastfeeding practices and infant and child mortality: a systematic review and meta-analysis. *Acta Paediatrica*. 2015; 104: 3-13.
2. Smith ER, Hurt L, Chowdhury R, et al. Delayed breastfeeding initiation and infant survival: A systematic review and meta-analysis. *PloS One*. 2017; 12: e0180722.
3. Andreas NJ, Kampmann B and Mehring Le-Doare K. Human breast milk: A review on its composition and bioactivity. *Early human development*. 2015; 91: 629-35.
4. Toscano M, De Grandi R, Peroni DG, et al. Impact of delivery mode on the colostrum microbiota composition. *BMC Microbiology*. 2017; 17: 205.
5. Michaelsen KF, Skafté L, Badsberg JH and Jorgensen M. Variation in macronutrients in human bank milk: influencing factors and implications for human milk banking. *Journal of Pediatric Gastroenterology and Nutrition*. 1990; 11: 229-39.
6. Ruiz L, Espinosa-Martos I, Garcia-Carral C, et al. What's Normal? Immune Profiling of Human Milk from Healthy Women Living in Different Geographical and Socioeconomic Settings. *Frontiers in Immunology*. 2017; 8: 696.
7. Powe CE, Knott CD and Conklin-Brittain N. Infant sex predicts breast milk energy content. *American Journal of Human Biology* 2010; 22: 50-4.
8. Riskin A, Almog M, Peri R, Halasz K, Srugo I and Kessel A. Changes in immunomodulatory constituents of human milk in response to active infection in the nursing infant. *Pediatric Research*. 2012; 71: 220-5.
9. Brandtzaeg P. Mucosal immunity: integration between mother and the breast-fed infant. *Vaccine*. 2003; 21: 3382-8.
10. Moles JP, Tuaillon E, Kankasa C, et al. Breastfeeding-related maternal microchimerism. *Nature Reviews Immunology*. 2017; 17: 729-1.

11. Moles JP, Tuaillon E, Kankasa C, et al. Breastmilk cell trafficking induces microchimerism-mediated immune system maturation in the infant. *Pediatric Allergy and Immunology* 2018; 29: 133-43.
12. Latuga MS, Stuebe A and Seed PC. A review of the source and function of microbiota in breast milk. *Seminars in Reproductive Medicine*. 2014; 32: 68-73.
13. Ward RE, Ninonuevo M, Mills DA, Lebrilla CB and German JB. In vitro fermentation of breast milk oligosaccharides by *Bifidobacterium infantis* and *Lactobacillus gasseri*. *Applied and Environmental Microbiology*. 2006; 72: 4497-9.
14. Hill DR, Huang S, Nagy MS, et al. Bacterial colonization stimulates a complex physiological response in the immature human intestinal epithelium. *eLife*. 2017; 6.
15. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. *The Journal of Infectious Diseases*. 2001; 183: 206-12.
16. Bunders MJ, van der Loos CM, Klarenbeek PL, et al. Memory CD4(+)CCR5(+) T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. *Blood*. 2012; 120: 4383-90.
17. Prendergast AJ, Klenerman P and Goulder PJ. The impact of differential antiviral immunity in children and adults. *Nature Reviews Immunology*. 2012; 12: 636-48.
18. Cottrell EB, Chou R, Wasson N, Rahman B and Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*. 2013; 158: 109-13.
19. Shi Z, Yang Y, Wang H, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. *Archives of Pediatrics & Adolescent Medicine*. 2011; 165: 837-46.



20. McGeoch DJ, Dolan A and Ralph AC. Toward a comprehensive phylogeny for mammalian and avian herpesviruses. *Journal of Virology*. 2000; 74: 10401-6.
21. Pass RF. Epidemiology and transmission of cytomegalovirus. *The Journal of Infectious Diseases*. 1985; 152: 243-8.
22. Kaye S, Miles D, Antoine P, et al. Virological and immunological correlates of mother-to-child transmission of cytomegalovirus in The Gambia. *The Journal of Infectious Diseases*. 2008; 197: 1307-14.
23. Cannon MJ, Schmid DS and Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Reviews in Medical Virology*. 2010; 20: 202-13.
24. Kurath S, Halwachs-Baumann G, Muller W and Resch B. Transmission of cytomegalovirus via breast milk to the prematurely born infant: a systematic review. *Clinical Microbiology and Infection* 2010; 16: 1172-8.
25. Hayashi S, Kimura H, Oshiro M, et al. Transmission of cytomegalovirus via breast milk in extremely premature infants. *Journal of Perinatology* 2011; 31: 440-5.
26. Hamprecht K, Maschmann J, Vochem M, Dietz K, Speer CP and Jahn G. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. *Lancet*. 2001; 357: 513-8.
27. Jim WT, Shu CH, Chiu NC, et al. High cytomegalovirus load and prolonged virus excretion in breast milk increase risk for viral acquisition by very low birth weight infants. *The Pediatric Infectious Disease Journal*. 2009; 28: 891-4.
28. Martins-Celini FP, Yamamoto AY, Passos DM, et al. Incidence, Risk Factors, and Morbidity of Acquired Postnatal Cytomegalovirus Infection Among Preterm Infants Fed Maternal Milk in a Highly Seropositive Population. *Clinical Infectious Diseases* 2016; 63: 929-36.

29. Boucoiran I, Mayer BT, Krantz EM, et al. Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants. *The Pediatric Infectious Disease Journal*. 2018; 37: 627-31.
30. Lanzieri TM, Dollard SC, Josephson CD, Schmid DS and Bialek SR. Breast milk-acquired cytomegalovirus infection and disease in VLBW and premature infants. *Pediatrics*. 2013; 131: e1937-45.
31. Bevot A, Hamprecht K, Krageloh-Mann I, Brosch S, Goelz R and Vollmer B. Long-term outcome in preterm children with human cytomegalovirus infection transmitted via breast milk. *Acta Paediatrica*. 2012; 101: e167-72.
32. Goelz R, Meisner C, Bevot A, Hamprecht K, Krageloh-Mann I and Poets CF. Long-term cognitive and neurological outcome of preterm infants with postnatally acquired CMV infection through breast milk. *Archives of Disease in Childhood Fetal and Neonatal Edition*. 2013; 98: F430-3.
33. Jim WT, Chiu NC, Ho CS, et al. Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection via Breast Milk: A Two-Year Prospective Follow-Up Study. *Medicine*. 2015; 94: e1835.
34. Hamprecht K and Goelz R. Postnatal Cytomegalovirus Infection Through Human Milk in Preterm Infants: Transmission, Clinical Presentation, and Prevention. *Clinics in Perinatology*. 2017; 44: 121-30.
35. Ben-Shoshan M, Mandel D, Lubetzky R, Dollberg S and Mimouni FB. Eradication of Cytomegalovirus from Human Milk by Microwave Irradiation: A Pilot Study. *Breastfeeding Medicine* 2016; 11: 186-7.
36. Hosseini M, Esmaili HA, Abdoli Oskouei S, et al. Evaluation of the Freeze-Thawing Method in Reducing Viral Load of Cytomegalovirus in Breast Milk of Mothers of Preterm Infants. *Breastfeeding Medicine* 2016; 11: 557-60.

37. Lloyd ML, Hod N, Jayaraman J, et al. Inactivation of Cytomegalovirus in Breast Milk Using Ultraviolet-C Irradiation: Opportunities for a New Treatment Option in Breast Milk Banking. *PloS One*. 2016; 11: e0161116.
38. Stock K, Griesmaier E, Brunner B, Neubauer V, Kiechl-Kohlendorfer U and Trawoger R. Pasteurization of breastmilk decreases the rate of postnatally acquired cytomegalovirus infections, but shows a nonsignificant trend to an increased rate of necrotizing enterocolitis in very preterm infants--a preliminary study. *Breastfeeding Medicine* 2015; 10: 113-7.
39. Picaud JC, Buffin R, Gremmo-Feger G, et al. Review concludes that specific recommendations are needed to harmonise the provision of fresh mother's milk to their preterm infants. *Acta Paediatrica*. 2018; 107: 1145-55.
40. Musonda KG, Nyonda M, Filteau S, Kasonka L, Monze M and Gompels UA. Increased Cytomegalovirus Secretion and Risks of Infant Infection by Breastfeeding Duration From Maternal Human Immunodeficiency Virus Positive Compared to Negative Mothers in Sub-Saharan Africa. *Journal of the Pediatric Infectious Diseases Society*. 2016; 5: 138-46.
41. Slyker J, Farquhar C, Atkinson C, et al. Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection. *Clinical Infectious Diseases* 2014; 58: 564-72.
42. Richardson BA, John-Stewart G, Atkinson C, et al. Vertical Cytomegalovirus Transmission From HIV-Infected Women Randomized to Formula-Feed or Breastfeed Their Infants. *The Journal of Infectious Diseases*. 2016; 213: 992-8.
43. Adland E, Klenerman P, Goulder P and Matthews PC. Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. *Frontiers in Microbiology*. 2015; 6: 1016.
44. Filteau S and Rowland-Jones S. Cytomegalovirus Infection May Contribute to the Reduced Immune Function, Growth, Development, and Health of HIV-Exposed, Uninfected African Children. *Frontiers in Immunology*. 2016; 7: 257.

45. Frederick T, Homans J, Spencer L, et al. The effect of prenatal highly active antiretroviral therapy on the transmission of congenital and perinatal/early postnatal cytomegalovirus among HIV-infected and HIV-exposed infants. *Clinical Infectious Diseases* 2012; 55: 877-84.
46. Giuliano M, Pirillo MF, Liotta G, et al. Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy. *Clinical Microbiology and Infection* 2017; 23: 491-2.
47. Meyer SA, Westreich DJ, Patel E, et al. Postnatal cytomegalovirus exposure in infants of antiretroviral-treated and untreated HIV-infected mothers. *Infectious Diseases in Obstetrics and Gynecology*. 2014; 2014: 989721.
48. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD and Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*. 1980; 77: 7415-9.
49. Gessain A and Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. *Frontiers in Microbiology*. 2012; 3: 388.
50. Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. *International Journal of Cancer*. 1989; 43: 250-3.
51. Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1996; 13 Suppl 1: S20-5.
52. Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. *Blood*. 2015; 126: 2570-7.

53. Varandas CMN, da Silva JLS, Primo JRL, et al. Early Juvenile Human T-cell Lymphotropic Virus Type-1-Associated Myelopathy/Tropical Spastic Paraparesis: Study of 25 Patients. *Clinical Infectious Diseases* 2018; 67: 1427-33.
54. Wiktor SZ, Pate EJ, Rosenberg PS, et al. Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. *Journal of Human Virology*. 1997; 1: 37-44.
55. Li HC, Biggar RJ, Miley WJ, et al. Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I. *The Journal of Infectious Diseases*. 2004; 190: 1275-8.
56. Ureta-Vidal A, Angelin-Duclos C, Tortevoe P, et al. Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. *International Journal of Cancer*. 1999; 82: 832-6.
57. Fuchi N, Miura K, Tsukiyama T, et al. Natural Course of Human T-Cell Leukemia Virus Type 1 Proviral DNA Levels in Carriers During Pregnancy. *The Journal of Infectious Diseases*. 2018; 217: 1383-9.
58. Percher F, Jeannin P, Martin-Latil S, et al. Mother-to-Child Transmission of HTLV-1 Epidemiological Aspects, Mechanisms and Determinants of Mother-to-Child Transmission. *Viruses*. 2016; 8.
59. Hino S. Establishment of the milk-borne transmission as a key factor for the peculiar endemicity of human T-lymphotropic virus type 1 (HTLV-1): the ATL Prevention Program Nagasaki. *Proceedings of the Japan Academy Series B, Physical and biological sciences*. 2011; 87: 152-66.
60. Martin F, Tagaya Y and Gallo R. Time to eradicate HTLV-1: an open letter to WHO. *Lancet*. 2018; 391: 1893-4.
61. UNAIDS Data 2018. Available at <http://www.unaids.org/en/resources/documents/2018/unaids-data-2018>.

62. Breastfeeding and HIV International Transmission Study Group, Coutoudis A, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. *The Journal of Infectious Diseases*. 2004; 189: 2154-66.
63. World Health Organization. HIV transmission through breastfeeding : a review of available evidence. 2007 update. WHO, Geneva, 2008. Available at <http://apps.who.int/iris/handle/10665/43879>.
64. Bispo S, Chikhungu L, Rollins N, Siegfried N and Newell ML. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis. *Journal of the International AIDS Society*. 2017; 20: 21251.
65. Ndirangu J, Viljoen J, Bland RM, et al. Cell-free (RNA) and cell-associated (DNA) HIV-1 and postnatal transmission through breastfeeding. *PloS One*. 2012; 7: e51493.
66. Van de Perre P, Simonon A, Hitimana DG, et al. Infective and anti-infective properties of breastmilk from HIV-1-infected women. *Lancet*. 1993; 341: 914-8.
67. Lunney KM, Iliff P, Mutasa K, et al. Associations between breast milk viral load, mastitis, exclusive breast-feeding, and postnatal transmission of HIV. *Clinical Infectious Diseases* 2010; 50: 762-9.
68. Iliff PJ, Piwoz EG, Tavengwa NV, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. *AIDS*. 2005; 19: 699-708.
69. Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial. *Journal of Acquired Immune Deficiency Syndromes*. 2018; 77: 383-92.
70. Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding

up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. *Lancet*.

2016; 387: 566-73.

71. Humphrey JH, Marinda E, Mutasa K, et al. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. *BMJ*. 2010; 341: c6580.

72. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. *The Journal of Experimental Medicine*. 2004; 200: 749-59.

73. Koulinska IN, Villamor E, Chaplin B, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. *Journal of Acquired Immune Deficiency Syndromes*. 2006; 41: 93-9.

74. Valea D, Tuaillon E, Al Tabaa Y, et al. CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs. *Retrovirology*. 2011; 8: 34.

75. Viljoen J, Tuaillon E, Nagot N, et al. Cytomegalovirus, and possibly Epstein-Barr virus, shedding in breast milk is associated with HIV-1 transmission by breastfeeding. *AIDS* 2015; 29: 145-53.

76. New data on the prevention of mother-to-child transmission of HIV and their policy implications : conclusions and recommendations : WHO Technical consultation on behalf of the UNFPA/UNICEF/WHO/UNAIDS Inter-Agency Task Team on Mother-to-Child Transmission of HIV, Geneva, 11-13 October 2000. Available at

<http://apps.who.int/iris/handle/10665/66851>.

77. WHO Special Programme on AIDS. (1987). Special Programme on AIDS statement : breast-feeding/breast milk and human immunodeficiency virus (HIV. Geneva : World Health Organization). Available at <http://www.who.int/iris/handle/10665/60788>

78. World Health Organization Technical Consultation: Towards the elimination of mother-to-child transmission of HIV: Report of a technical consultation, Geneva, November 2010. Available from [http://whqlibdoc.who.int/publications/2011/9789241501910\\_eng.pdf?ua=1](http://whqlibdoc.who.int/publications/2011/9789241501910_eng.pdf?ua=1). Accessed 7 June 2018.
79. UNFPA, UNICEF, WHO, UNAIDS, on behalf of the Inter-Agency Task Team: New Data on the Prevention of Mother-To-Child Transmission of HIV and their Policy Implications. Conclusions and Recommendations. WHO Technical Consultation, 11-13 October 2000. Available from: <http://apps.who.int/iris/handle/10665/66851?locale=es&locale=zh&locale=en&locale=ar>.
80. World Health Organization: Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach (2010 revision). Available from [http://www.who.int/hiv/pub/mtct/arv\\_guidelines\\_mtct.pdf](http://www.who.int/hiv/pub/mtct/arv_guidelines_mtct.pdf).
81. Eamer GG and Randall GE. Barriers to implementing WHO's exclusive breastfeeding policy for women living with HIV in sub-Saharan Africa: an exploration of ideas, interests and institutions. *The International Journal of Health Planning and Management*. 2013; 28: 257-68.
82. World Health Organization: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. WHO, 2012. Available from [http://www.who.int/hiv/pub/mtct/programmatic\\_update2012/en/](http://www.who.int/hiv/pub/mtct/programmatic_update2012/en/).
83. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach - Second edition. WHO, Geneva 2016. Available at <http://www.who.int/hiv/pub/arv/arv-2016/en/>.



84. World Health Organization: Global Guidance on Criteria and Processes for Validation: Elimination of mother-to-child transmission of HIV and syphilis. WHO, 2014. Available from <http://www.who.int/hiv/pub/emtct-validation-guidance/en/>. .
85. Haas AD, Msukwa MT, Egger M, et al. Adherence to Antiretroviral Therapy During and After Pregnancy: Cohort Study on Women Receiving Care in Malawi's Option B+ Program. *Clinical Infectious Diseases* 2016; 63: 1227-35.
86. Myer L, Essajee S, Broyles LN, et al. Pregnant and breastfeeding women: A priority population for HIV viral load monitoring. *PLoS Medicine*. 2017; 14: e1002375.
87. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. *AIDS*. 2012; 26: 2039-52.
88. Ziegler JB, Cooper DA, Johnson RO and Gold J. Postnatal transmission of AIDS-associated retrovirus from mother to infant. *Lancet*. 1985; 1: 896-8.
89. Thiry L, Sprecher-Goldberger S, Jonckheer T, et al. Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers. *Lancet*. 1985; 2: 891-2.
90. CDC. Current Trends Recommendations for Assisting in the Prevention of Perinatal Transmission of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus and Acquired Immunodeficiency Syndrome. MMWR 34(48):721-6. Available at <https://http://www.cdc.gov/mmwr/preview/mmwrhtml/00033122.htm>.
91. Wolf LE, Lo B, Beckerman KP, Dorenbaum A, Kilpatrick SJ and Weinrub PS. When parents reject interventions to reduce postnatal human immunodeficiency virus transmission. *Archives of Pediatrics & Adolescent Medicine*. 2001; 155: 927-33.
92. Homsy J, Moore D, Barasa A, et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda. *Journal of Acquired Immune Deficiency Syndromes*. 2010; 53: 28-35.

93. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. *Journal of Acquired Immune Deficiency Syndromes*. 2009; 52: 406-16.
94. Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. *The Pediatric Infectious Disease Journal*. 2009; 28: 483-7.
95. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. *The New England Journal of Medicine*. 2010; 362: 2271-81.
96. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. *The New England Journal of Medicine*. 2010; 362: 2282-94.
97. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. Available at <https://http://www.bhiva.org/pregnancy-guidelines>.
98. European AIDS Clinical Society. Guidelines Version 9.1, October 2018. Available at <http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>.
99. US Department of Health and Human Services. Guidance for Counseling and Managing Women Living with HIV in the United States Who Desire to Breastfeed. March 27, 2018. Available at <https://aidsinfo.nih.gov/guidelines/html/3/perinatal/513/guidance-for-counseling-and-managing-women-living-with-hiv-in-the-united-states-who-desire-to-breastfeed>.
100. Waitt C, Olagunju A, Nakalema S, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. *The Journal of Antimicrobial Chemotherapy*. 2018; 73: 1013-9.
101. Waitt CJ, Garner P, Bonnett LJ, Khoo SH and Else LJ. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and

meta-analysis of pharmacokinetic studies. *The Journal of Antimicrobial Chemotherapy*. 2015; 70: 1928-41.

102. Olagunju A, Bolaji O, Amara A, et al. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. *Clinical Infectious Diseases* 2015; 61: 453-63.

103. Nachega JB, Uthman OA, Mofenson LM, et al. Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. *Journal of Acquired Immune Deficiency Syndromes*. 2017; 76: 1-12.

104. Orrell C, Kintu K, Coombs JA, et al. DolPHIN-1: Randomised controlled trial of dolutegravir(DTG)-versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy. *22nd International AIDS Conference*. Amsterdam, Netherlands 2018.

105. Hawcutt DB, Russell NJ, Maqsood H, et al. Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis. *British Journal of Clinical Pharmacology*. 2016; 82: 1601-12.

106. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. *Clinical Infectious Diseases* 2011; 52: 1069-76.

107. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. *PLoS Medicine*. 2011; 8: e1000430.

108. Inzaule SC, Weidle PJ, Yang C, et al. Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine,

zidovudine and either nevirapine or nelfinavir in breast milk. *The Journal of Antimicrobial Chemotherapy*. 2016; 71: 1619-26.

109. Mazanderani AH, Moyo F, Kufa T and Sherman GG. Brief Report: Declining Baseline Viremia and Escalating Discordant HIV-1 Confirmatory Results Within South Africa's Early Infant Diagnosis Program, 2010-2016. *Journal of Acquired Immune Deficiency Syndromes*. 2018; 77: 212-6.

110. Phiri S, Tweya H, van Lettow M, et al. Impact of Facility- and Community-Based Peer Support Models on Maternal Uptake and Retention in Malawi's Option B+ HIV Prevention of Mother-to-Child Transmission Program: A 3-Arm Cluster Randomized Controlled Trial (PURE Malawi). *Journal of Acquired Immune Deficiency Syndromes*. 2017; 75 Suppl 2: S140-S8.

## **Figure legends**

**Figure 1:** Balancing the benefits and risks of breastfeeding in the context of breast milk viral transmission.

**Figure 2:** Factors influencing drug exposure in the breastfed infant.

**Table 1. Biological and epidemiological characteristics of human viruses transmitted by breastfeeding**

Characteristic	HTLV-1	HIV-1	CMV
Rate of shedding in breast milk (PCR)	>80% (HTLV-1 DNA)	20-60% (HIV RNA and/or DNA)	>80% seropositive mothers (CMV DNA)
Mode of excretion in breast milk	Cell-associated	Cell-free and cell-associated	Cell-free and cell-associated
Transmission rate by breastfeeding in the absence of prevention	Transmission occurs in 10-25% of breastfed infants	0.74% transmission per month of breastfeeding	80 to 90% infants infected by 12 months in LMIC; 20-40% in high-income settings
Risk factors for breastfeeding transmission	<p>Duration of breastfeeding</p> <p>Proviral load in breast milk and blood</p> <p>High titres of maternal anti-HTLV-1 antibodies</p>	<p>HIV RNA viral load in blood and/or in breast milk</p> <p>Duration of breastfeeding</p> <p>Early (before 6 months of life) addition of a replacement feed (mixed feeding)</p> <p>Severity of maternal immunodeficiency</p> <p>Absence of anti-HIV IgM and/or sIgA in breast milk</p> <p>Absence of HIV-specific cytotoxic T-cells in breast milk</p> <p>Mastitis and other inflammatory process in breast and breast milk</p>	<p>Duration of breastfeeding</p> <p>Earlier CMV excretion in milk</p> <p>Higher CMV viral load</p> <p>Trans-placental maternal anti-CMV IgG may be protective</p> <p>High-avidity anti-CMV IgG in breast milk may be protective</p>

Public health impact of breastfeeding transmission	Restricted to highly endemic regions Severe but infrequent clinical disease, mostly in adults (ATL, TSP/HAM)	Global pandemic, approximately 100,000 new pediatric infections attributed to breastfeeding transmission annually Frequent and severe disease if infant ART is not initiated early	Mostly asymptomatic Clinical disease in immunocompromised or very preterm infants, including sepsis-like illness Impact of breast milk transmission on growth and neurodevelopment uncertain
Prevention	In highly endemic areas: antenatal HTLV-1 testing and exclusive formula feeding Administration of freeze-d-thawed expressed breast milk Feeding by wet nurse or milk from healthy donors	High-income settings: Formula feeding recommended LMIC: Breastfeeding with maternal ART Infant post-exposure prophylaxis (currently recommended by WHO for six weeks or longer if risk of MTCT is high) Infant pre-exposure prophylaxis (currently not recommended by WHO) Pasteurisation of breast milk (currently not included in WHO guidelines) Potentially, passive immunoprophylaxis (under evaluation)	Uncertain Pasteurisation reduces transmission, but negative effects on other breast milk components Potentially freezing, ultraviolet-C irradiation and high-power microwave Role of antiviral interventions uncertain (toxicity, cost, efficacy)

PCR: Polymerase chain reaction; LMIC: Low- and middle-income countries; IgM: immunoglobulin M; sIgA: secretory immunoglobulin A; IgG: Immunoglobulin G; ATL: Adult T-cell leukaemia/lymphoma; TSP/HAM: Tropical spastic paraparesis / HTLV-1 associated myelopathy; ART: antiretroviral therapy; WHO: World Health Organization; MTCT: Mother-to-child transmission.





